Anacor Pharmaceuticals (Anacor Pharmaceuticals) Operating Income : $-59.50 Mil (TTM As of Mar. 2016)

View and export this data going back to 2010. Start your Free Trial

What is Anacor Pharmaceuticals Operating Income?

Anacor Pharmaceuticals's Operating Income for the three months ended in Mar. 2016 was $-14.92 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2016 was $-59.50 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Anacor Pharmaceuticals's Operating Income for the three months ended in Mar. 2016 was $-14.92 Mil. Anacor Pharmaceuticals's Revenue for the three months ended in Mar. 2016 was $17.54 Mil. Therefore, Anacor Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2016 was -85.09%.

Anacor Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anacor Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2016 was -560.31%. Anacor Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2016 was -2,547.85%.

Anacor Pharmaceuticals Operating Income Historical Data

The historical data trend for Anacor Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anacor Pharmaceuticals Operating Income Chart

Anacor Pharmaceuticals Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Operating Income

Get a 7-Day Free Trial

-46.34

-53.19

92.52

-90.80

-56.38

Anacor Pharmaceuticals Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Operating Income	Get a 7-Day Free Trial															-11.80	-12.00	-14.95	-17.64	-14.92

Anacor Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.50 Mil.

Anacor Pharmaceuticals (NAS:ANAC) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anacor Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2016 is calculated as:

	ROC % (Q: Mar. 2016 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2015 )	+	Invested Capital (Q: Mar. 2016 ))	/ count )
=	-59.684 * ( 1 - 0% )	/	( (10.658	+	10.646)	/ 2 )
=	-59.684	/	10.652
=	-560.31 %

where

	Invested Capital		(Q: Dec. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	176.102	-	24.858	-	( 142.361	-	max(0, 29.509	-	170.095	+	142.361	))
=	10.658

	Invested Capital		(Q: Mar. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	164.002	-	21.07	-	( 135.766	-	max(0, 25.012	-	157.298	+	135.766	))
=	10.646

Note: The Operating Income data used here is four times the quarterly (Mar. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

Anacor Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2016 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2016 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2015		Q: Mar. 2016
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-58.868	/	( ( (2.298 + max(-20.076, 0))	+	(2.323 + max(-18.426, 0)) )	/	2 )
=	-58.868	/	( ( 2.298	+	2.323 )	/	2 )
=	-58.868	/	2.3105
=	-2,547.85 %

where Working Capital is:

	Working Capital		(Q: Dec. 2015 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	2.925	+	6.508)	-	(24.858	+	4.651	+	0)
=	-20.076

	Working Capital		(Q: Mar. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	2.678	+	3.908)	-	(21.07	+	3.546	+	0.396)
=	-18.426

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2016) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Anacor Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2016 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2016 )	/	Revenue (Q: Mar. 2016 )
	=	-14.921	/	17.535
	=	-85.09 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Anacor Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Anacor Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Anacor Pharmaceuticals (Anacor Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anacor Pharmaceuticals Inc (NAS:ANAC) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.anacor.com

Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.

Executives

Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
William Jl Rieflin	director	NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anders D Hove	director	30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
Graeme Bell	officer: Executive VP and CFO	1324 WAVERLY ROAD, GLADWYNE PA 19035
Ryan T Sullivan	officer: EVP and General Counsel	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Paul L Berns	director, officer: President and CEO	11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Mark Leschly	director	RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019
Geoffrey M. Parker	officer: Executive Vice President & CFO	15 RIORDAN PLACE, MENLO PARK CA 94025
Paul H Klingenstein	director	428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
David P Perry	director, officer: President and CEO	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Rho Management Ventures Iv Llc	10 percent owner	124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Qp Lp	10 percent owner	124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Lp	10 percent owner	124 DUNE ROAD, QUOGUE NY 11959

Anacor Pharmaceuticals (Anacor Pharmaceuticals) Headlines

From GuruFocus

Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, Arctos NorthStar Acquisition Corp. Announces Receipt of NYSE Continued Listing Standard Notice

By Business Wire Business Wire • 06-02-2021

Arctos NorthStar Acquisition Corp. Announces Redemption of Class A Ordinary Shares

By Business Wire Business Wire • 02-10-2023